Hydroxocobalamin injection should not be used for the treatment of megaloblastic anaemia of pregnancy
It can increase heart rate and blood pressure, which means it is generally contraindicated for patients with a history of heart disease, hyperthyroidism, or uncontrolled high blood pressure
However, both medications can occasionally cause side effects that affect the liver or blood counts
Higher dose exploration (4.5mg trials) Rationale for testing 4.5mg: Investigate maximum tolerable dose Determine if higher = better weight loss Establish safety ceiling Results at 4.5mg weekly: Weight loss: ~12% (vs 10% at 2.4mg) Incremental benefit: Only 2% additional loss Side effects: Significantly worse nausea/vomiting Dropout rate: Higher than 2.4mg Clinical verdict: 4.5mg not recommended for routine use Risk-benefit ratio unfavorable 2.4mg remains optimal Some individuals may tolerate 3.0mg as compromise CagriSema combination dosing trials REDEFINE-1 protocol: Semaglutide: 2.4mg weekly (standard titration over 16 weeks) Cagrilintide: 2.4mg weekly (12-week titration) Both given as separate injections Started simultaneously from week 1 Semaglutide escalation (standard): Weeks 1-4: 0.25mg Weeks 5-8: 0.5mg Weeks 9-12: 1.0mg Weeks 13-16: 1.7mg Week 17+: 2.4mg Cagrilintide escalation (when combined): Weeks 1-4: 0.6mg Weeks 5-8: 1.2mg Weeks 9-12: 1.8mg Week 13+: 2.4mg Results: 15.6% average weight loss (68 weeks) Superior to either alone Side effects manageable with slow titration Combination well-tolerated See our cagrilintide and semaglutide combination guide and semaglutide dosage calculator
Additional testing - Doctors may recommend other blood panels, like a complete metabolic panel or thyroid tests
The value of the combo lies in **mechanistic divergence coupled with vascular convergence**: BPC-157 covers local cytoprotection and the gut-tendon axis, TB-500 covers systemic cell migration and stem-cell mobilization, and both converge on the neoangiogenesis required for deep tissue regeneration
